Technical Analysis for TRIL - Trillium Therapeutics In

Grade Last Price % Change Price Change
F 11.21 -3.61% -0.420
TRIL closed down 3.61 percent on Monday, May 10, 2021, on 70 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 13
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical TRIL trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
20 DMA Resistance Bearish -3.61%
NR7 Range Contraction -3.61%
Inside Day Range Contraction -3.61%
Fell Below 20 DMA Bearish -0.71%
180 Bearish Setup Bearish Swing Setup -0.71%
Crossed Above 20 DMA Bullish -8.42%
MACD Bullish Signal Line Cross Bullish -0.80%
NR7 Range Contraction -0.80%
Older End-of-Day Signals for TRIL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 14 hours ago
10 DMA Support about 18 hours ago
Down 3% about 18 hours ago
Fell Below Previous Day's Low about 18 hours ago
Down 2% about 18 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Trillium Therapeutics In Description

Trillium Therapeutics Inc is a Canada-based clinical stage immuno-oncology company developing therapies for the treatment of cancer. Its SIRPaFc (TTI-621) program, which is under Phase I clinical trial, is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the fragment crystallizable (Fc) region of a human immunoglobulin (IgG1). It acts as a soluble decoy receptor, preventing CD47 from delivering its inhibitory signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic signals. It also has a medicinal chemistry platform, which permits the creation of new chemical entities from validated drugs and drug candidates with managed pharmacological properties. Its preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds are in the discovery phase.


Sector: Healthcare
Industry: Biotechnology
Keywords: Chemistry Medicine Pharma Chemical Clinic Drug Drugs Cancer Clinical Trial Oncology Immunology Tumor Treatment Of Cancer Brain Cancer Immunotherapy Cell Biology Bromodomain Cancer Research Cd4 Medicinal Chemistry

Is TRIL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 27.12
52 Week Low 7.53
Average Volume 171,632
200-Day Moving Average 15.841
50-Day Moving Average 12.771
20-Day Moving Average 11.773
10-Day Moving Average 11.394
Average True Range 0.788
ADX 20.3
+DI 18.920
-DI 20.383
Chandelier Exit (Long, 3 ATRs ) 11.756
Chandelier Exit (Short, 3 ATRs ) 12.744
Upper Bollinger Band 12.984
Lower Bollinger Band 10.561
Percent B (%b) 0.27
BandWidth 20.578
MACD Line -0.467
MACD Signal Line -0.530
MACD Histogram 0.0627
Fundamentals Value
Market Cap 1.13 Billion
Num Shares 101 Million
EPS -2.11
Price-to-Earnings (P/E) Ratio -5.31
Price-to-Sales 10792.72
Price-to-Book 11.43
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 11.825
Resistance 3 (R3) 11.877 11.723 11.723
Resistance 2 (R2) 11.723 11.567 11.698 11.688
Resistance 1 (R1) 11.467 11.470 11.390 11.415 11.654
Pivot Point 11.313 11.313 11.275 11.288 11.313
Support 1 (S1) 11.057 11.157 10.980 11.005 10.766
Support 2 (S2) 10.903 11.060 10.878 10.732
Support 3 (S3) 10.647 10.903 10.698
Support 4 (S4) 10.595